RPS19 and Bone marrow hypocellularity: Their results revealed that recipients transduced with EFS-RPS19 shRNA BM exhibited near normal blood cellularity, indicating that enforced expression of RPS19 driven by the EFS promoter can effectively treat severe anemia and bone marrow failure in RPS19-deficient mice.